BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Metibemu DS, Akinloye OA, Akamo AJ, Ojo DA, Okeowo OT, Omotuyi IO. Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egypt J Med Hum Genet 2019;20. [DOI: 10.1186/s43042-019-0035-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Gaber AA, Sobhy M, Turky A, Abdulwahab HG, Al-Karmalawy AA, Elhendawy MA, Radwan MM, Elkaeed EB, Ibrahim IM, Elzahabi HSA, Eissa IH. Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M. J Enzyme Inhib Med Chem 2022;37:2283-303. [PMID: 36000168 DOI: 10.1080/14756366.2022.2112575] [Reference Citation Analysis]
2 Semba Y, Yamamoto S, Takahashi S, Shinomiya T, Nagahara Y. C-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175183] [Reference Citation Analysis]
3 Moosavi F, Damghani T, Ghazi S, Pirhadi S. In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents. J Recept Signal Transduct Res 2022;:1-13. [PMID: 35704515 DOI: 10.1080/10799893.2022.2086988] [Reference Citation Analysis]
4 Scott SS, Greenlee AN, Matzko A, Stein M, Naughton MT, Zaramo TZ, Schwendeman EJ, Mohammad SJ, Diallo M, Revan R, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. Heart Failure Clinics 2022. [DOI: 10.1016/j.hfc.2022.02.003] [Reference Citation Analysis]
5 Naomi R, Bahari H, Ong ZY, Keong YY, Embong H, Rajandram R, Teoh SH, Othman F, Hasham R, Yin KB, Kaniappan P, Yazid MD, Zakaria ZA. Mechanisms of Natural Extracts of Andrographis paniculata That Target Lipid-Dependent Cancer Pathways: A View from the Signaling Pathway. IJMS 2022;23:5972. [DOI: 10.3390/ijms23115972] [Reference Citation Analysis]
6 Salimi-Jeda A, Ghabeshi S, Gol Mohammad Pour Z, Jazaeri EO, Araiinejad M, Sheikholeslami F, Abdoli M, Edalat M, Abdoli A. Autophagy Modulation and Cancer Combination Therapy: A Smart Approach in Cancer Therapy. Cancer Treat Res Commun 2022;30:100512. [PMID: 35026533 DOI: 10.1016/j.ctarc.2022.100512] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Das R, Choithramani A, Shard A. A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics. Drug Discov Today 2021:S1359-6446(21)00543-2. [PMID: 34920095 DOI: 10.1016/j.drudis.2021.12.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bu Y, Zhang X, Zhu A, Li L, Xie X, Wang S. Inside-Out-Oriented Cell Membrane Biomimetic Magnetic Nanoparticles for High-Performance Drug Lead Discovery. Anal Chem 2021;93:7898-907. [PMID: 34038073 DOI: 10.1021/acs.analchem.1c00567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Porębska N, Poźniak M, Matynia A, Żukowska D, Zakrzewska M, Otlewski J, Opaliński Ł. Galectins as modulators of receptor tyrosine kinases signaling in health and disease. Cytokine Growth Factor Rev 2021;60:89-106. [PMID: 33863623 DOI: 10.1016/j.cytogfr.2021.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Alkamaly OM, Altwaijry N, Sabour R, Harras MF. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives. Arch Pharm (Weinheim) 2021;354:e2000351. [PMID: 33252142 DOI: 10.1002/ardp.202000351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gilchrist VH, Jémus-Gonzalez E, Said A, Alain T. Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy. Cytokine Growth Factor Rev 2020;56:83-93. [PMID: 32690442 DOI: 10.1016/j.cytogfr.2020.07.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]